Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364066 | 1.00 | MGAM (0.37) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL15698708 | 0.84 | MGAM (0.47) | MGAMGAASIMGAM2TSHR | |
| Ammonia Solution, Strong SCHEMBL6402119 | 0.81 | CTSK (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL6402123 | 0.81 | CTSK (0.36) | — | |
| SCHEMBL4145829 | 0.80 | GRIK1 (0.32) | ALDH1A1 | |
| SCHEMBL4145834 | 0.80 | GRIK1 (0.32) | ALDH1A1 | |
| SCHEMBL13851870 | 0.80 | GRIK1 (0.32) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL6400229 | 0.78 | GRIK1 (0.32) | ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL6400231 | 0.78 | GRIK1 (0.32) | ALDH1A1 | |
| Potassium Ion SCHEMBL6395315 | 0.77 | CA4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230135-B2 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | WARNER LAMBERT COMPANY LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-6891059-B2 | Asymmetric synthesis of pregabalin | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1341799-B1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | WARNER LAMBERT CO (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040215027-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART | 2004-10-28 | — | — | US | disclosed |
| US-6750171-B2 | IMPROVE ENANTIOSELECTIVITY IN ASYMMETRIC REACTIONS | WARNER-LAMBERT COMPANY LLC | 2004-06-15 | — | — | US | disclosed |
| EP-1250311-B1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030236433-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | BURK MARK JOSEPH (US) | 2003-11-13 | — | — | US | disclosed |
| EP-1341799-A1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | Warner-Lambert Company LLC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6605745-B2 | Locates chirality closer to the metal center than known metal phospholane complexes; provide high enantiomeric excesses of formed compounds | HOGE II GARRETT STEWART (US) | 2003-08-12 | — | — | US | disclosed |
| EP-1250311-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | HOGE GARRETT STEWART (US) | 2002-07-04 | — | — | US | disclosed |
| WO-2002048161-A1 | P-CHIRALE BISPHOSPHOLANE LIGANDS, THEIR TRANSITION METAL COMPLEXES | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001055090-A1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215027-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | MGAM 497/4885GAA 3149/4885SI 2423/4885 |
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | GABRA5, GABRA6, GABRE | MGAM 1223/4885GAA 3133/4885SI 1615/4885 |
| US-20030236433-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | MGAM 497/4885GAA 3149/4885SI 2423/4885 |
| US-20020087017-A1 | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | PHOSPHO1, BPGM, PHPT1 | MGAM 497/4885GAA 3149/4885SI 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.